Results 211 to 220 of about 1,371,111 (294)

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

open access: yesBMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang   +7 more
wiley   +1 more source

GelMA‐Based Hydrogel Encapsulating Astragalus Polysaccharides and Umbilical Cord Mesenchymal Stem Cell Exosomes Promotes Full‐Thickness Skin Wound Healing

open access: yesChronic Diseases and Translational Medicine, EarlyView.
ABSTRACT Background Wound healing involves excessive oxidative stress and cellular dysfunction, while current single therapies remain inadequate. Astragalus polysaccharides (APS) and exosomes (Exos) possess antioxidative and regenerative properties, and gelatin methacryloyl (GelMA) hydrogel provides a biocompatible platform for localized delivery. Here,
Jingwen Tian   +7 more
wiley   +1 more source

Transcriptomic Profiling of SLC and ABC Transporters in the Human Term Placenta

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Solute carriers (SLC) and ATP‐binding cassette (ABC) transporters are essential for placental solute exchange and fetal protection, yet their transcriptomic profiles in the human placenta remain poorly characterized. Although fetal sex influences placental development and function, its impact on transporter expression is unclear.
Elijah Marsh Jung   +12 more
wiley   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit   +6 more
wiley   +1 more source

The Value of Lung Biopsy in Infants up to 3 Months With Diffuse Lung Disease in a Resource-Limited Setting. [PDF]

open access: yesCan Respir J
Goussard P   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy